EA024697B1 - Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени - Google Patents

Info

Publication number

EA024697B1

EA024697B1 EA201171304A EA201171304A EA024697B1 EA 024697 B1 EA024697 B1 EA 024697B1 EA 201171304 A EA201171304 A EA 201171304A EA 201171304 A EA201171304 A EA 201171304A EA 024697 B1 EA024697 B1 EA 024697B1

Authority

EA

Eurasian Patent Office

Prior art keywords

cells

colostrum

liver

antibodies

composition

Prior art date

2009-04-27

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 title claims abstract description 212
• 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 195
• 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 195
• 238000002360 preparation method Methods 0.000 title claims abstract description 194
• 208000019423 liver disease Diseases 0.000 title claims abstract description 46
• 238000011282 treatment Methods 0.000 title claims description 61
• 235000021277 colostrum Nutrition 0.000 claims abstract description 244
• 210000003022 colostrum Anatomy 0.000 claims abstract description 244
• 208000004930 Fatty Liver Diseases 0.000 claims abstract description 20
• 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 15
• 208000010706 fatty liver disease Diseases 0.000 claims abstract description 15
• 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 15
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 26
• 108010082126 Alanine transaminase Proteins 0.000 claims description 26
• 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 21
• 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 21
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 21
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 21
• 208000005176 Hepatitis C Diseases 0.000 claims description 3
• 208000006154 Chronic hepatitis C Diseases 0.000 claims description 2
• 208000010710 hepatitis C virus infection Diseases 0.000 claims description 2
• 108090000340 Transaminases Proteins 0.000 claims 2
• 102000003929 Transaminases Human genes 0.000 claims 2
• 208000007386 hepatic encephalopathy Diseases 0.000 abstract description 8
• 230000002440 hepatic effect Effects 0.000 abstract description 5
• 230000001476 alcoholic effect Effects 0.000 abstract description 2
• 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 abstract 1
• 208000020403 chronic hepatitis C virus infection Diseases 0.000 abstract 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 206
• 210000004027 cell Anatomy 0.000 description 184
• 208000035475 disorder Diseases 0.000 description 126
• 239000000427 antigen Substances 0.000 description 117
• 108091007433 antigens Proteins 0.000 description 117
• 102000036639 antigens Human genes 0.000 description 117
• 210000004185 liver Anatomy 0.000 description 117
• 241000699670 Mus sp. Species 0.000 description 92
• 210000001744 T-lymphocyte Anatomy 0.000 description 81
• 201000010099 disease Diseases 0.000 description 80
• 230000028993 immune response Effects 0.000 description 73
• 238000000034 method Methods 0.000 description 73
• 210000004698 lymphocyte Anatomy 0.000 description 72
• 210000000987 immune system Anatomy 0.000 description 69
• 102400000401 Latency-associated peptide Human genes 0.000 description 65
• 210000003289 regulatory T cell Anatomy 0.000 description 64
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 55
• 210000000952 spleen Anatomy 0.000 description 55
• 230000000694 effects Effects 0.000 description 49
• 230000006698 induction Effects 0.000 description 49
• 210000000577 adipose tissue Anatomy 0.000 description 45
• 241000283690 Bos taurus Species 0.000 description 39
• 238000004458 analytical method Methods 0.000 description 39
• 239000003814 drug Substances 0.000 description 38
• 230000014509 gene expression Effects 0.000 description 36
• 230000001575 pathological effect Effects 0.000 description 36
• 210000002966 serum Anatomy 0.000 description 35
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 33
• 210000001519 tissue Anatomy 0.000 description 33
• 229940079593 drug Drugs 0.000 description 32
• 208000019425 cirrhosis of liver Diseases 0.000 description 31
• 230000007423 decrease Effects 0.000 description 31
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 31
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
• 239000002671 adjuvant Substances 0.000 description 30
• 239000012634 fragment Substances 0.000 description 30
• 239000008103 glucose Substances 0.000 description 30
• 244000005700 microbiome Species 0.000 description 30
• 206010016654 Fibrosis Diseases 0.000 description 29
• 230000001154 acute effect Effects 0.000 description 29
• 230000007882 cirrhosis Effects 0.000 description 29
• 230000002265 prevention Effects 0.000 description 29
• 208000001145 Metabolic Syndrome Diseases 0.000 description 28
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 28
• 229940125396 insulin Drugs 0.000 description 28
• 102000004877 Insulin Human genes 0.000 description 27
• 108090001061 Insulin Proteins 0.000 description 27
• 241001465754 Metazoa Species 0.000 description 27
• 150000003626 triacylglycerols Chemical class 0.000 description 27
• 102000004127 Cytokines Human genes 0.000 description 26
• 108090000695 Cytokines Proteins 0.000 description 26
• 230000001965 increasing effect Effects 0.000 description 25
• 230000005945 translocation Effects 0.000 description 25
• 229940072221 immunoglobulins Drugs 0.000 description 24
• 208000015181 infectious disease Diseases 0.000 description 24
• 230000002401 inhibitory effect Effects 0.000 description 24
• 235000013336 milk Nutrition 0.000 description 24
• 239000008267 milk Substances 0.000 description 24
• 210000004080 milk Anatomy 0.000 description 24
• 230000003110 anti-inflammatory effect Effects 0.000 description 22
• 208000023275 Autoimmune disease Diseases 0.000 description 21
• 238000000684 flow cytometry Methods 0.000 description 21
• 238000003307 slaughter Methods 0.000 description 21
• 230000004913 activation Effects 0.000 description 20
• 235000013601 eggs Nutrition 0.000 description 20
• 230000000770 proinflammatory effect Effects 0.000 description 20
• 230000001105 regulatory effect Effects 0.000 description 20
• 208000030090 Acute Disease Diseases 0.000 description 19
• 210000000612 antigen-presenting cell Anatomy 0.000 description 19
• 230000001684 chronic effect Effects 0.000 description 19
• 206010012601 diabetes mellitus Diseases 0.000 description 19
• 230000002519 immonomodulatory effect Effects 0.000 description 19
• 208000011580 syndromic disease Diseases 0.000 description 18
• 208000035473 Communicable disease Diseases 0.000 description 17
• 206010067125 Liver injury Diseases 0.000 description 17
• 210000001789 adipocyte Anatomy 0.000 description 17
• 210000002969 egg yolk Anatomy 0.000 description 17
• 230000006870 function Effects 0.000 description 17
• 231100000234 hepatic damage Toxicity 0.000 description 17
• 230000008818 liver damage Effects 0.000 description 17
• 238000004519 manufacturing process Methods 0.000 description 17
• 210000005167 vascular cell Anatomy 0.000 description 17
• 241000894006 Bacteria Species 0.000 description 16
• 206010022489 Insulin Resistance Diseases 0.000 description 16
• 235000012000 cholesterol Nutrition 0.000 description 16
• 238000002474 experimental method Methods 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 241000124008 Mammalia Species 0.000 description 15
• 210000004369 blood Anatomy 0.000 description 15
• 239000008280 blood Substances 0.000 description 15
• 238000011161 development Methods 0.000 description 15
• 230000018109 developmental process Effects 0.000 description 15
• 241000700605 Viruses Species 0.000 description 14
• 230000003213 activating effect Effects 0.000 description 14
• 208000006454 hepatitis Diseases 0.000 description 14
• 230000002062 proliferating effect Effects 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• 108090000623 proteins and genes Proteins 0.000 description 14
• 102000004169 proteins and genes Human genes 0.000 description 14
• 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 14
• 208000008589 Obesity Diseases 0.000 description 13
• 230000001404 mediated effect Effects 0.000 description 13
• 235000020824 obesity Nutrition 0.000 description 13
• 201000001320 Atherosclerosis Diseases 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 206010028980 Neoplasm Diseases 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• 210000000936 intestine Anatomy 0.000 description 12
• 210000000056 organ Anatomy 0.000 description 12
• 208000032843 Hemorrhage Diseases 0.000 description 11
• 206010046996 Varicose vein Diseases 0.000 description 11
• 208000034158 bleeding Diseases 0.000 description 11
• 230000000740 bleeding effect Effects 0.000 description 11
• 239000002552 dosage form Substances 0.000 description 11
• 239000003925 fat Substances 0.000 description 11
• 230000003053 immunization Effects 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 238000010186 staining Methods 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• 235000013365 dairy product Nutrition 0.000 description 10
• 230000003211 malignant effect Effects 0.000 description 10
• 238000012545 processing Methods 0.000 description 10
• 208000027185 varicose disease Diseases 0.000 description 10
• 235000010469 Glycine max Nutrition 0.000 description 9
• 230000027455 binding Effects 0.000 description 9
• 210000001035 gastrointestinal tract Anatomy 0.000 description 9
• 230000007246 mechanism Effects 0.000 description 9
• 244000052769 pathogen Species 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 230000028327 secretion Effects 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 238000002054 transplantation Methods 0.000 description 9
• 229960005486 vaccine Drugs 0.000 description 9
• 206010003445 Ascites Diseases 0.000 description 8
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 108010002212 colostrinine Proteins 0.000 description 8
• 230000002708 enhancing effect Effects 0.000 description 8
• 230000000521 hyperimmunizing effect Effects 0.000 description 8
• 230000005934 immune activation Effects 0.000 description 8
• 230000000968 intestinal effect Effects 0.000 description 8
• 238000002955 isolation Methods 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 108090000765 processed proteins & peptides Proteins 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 102000002322 Egg Proteins Human genes 0.000 description 7
• 108010000912 Egg Proteins Proteins 0.000 description 7
• 241000287828 Gallus gallus Species 0.000 description 7
• 208000002705 Glucose Intolerance Diseases 0.000 description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 206010033307 Overweight Diseases 0.000 description 7
• 206010062070 Peritonitis bacterial Diseases 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 231100000283 hepatitis Toxicity 0.000 description 7
• 201000011200 hepatorenal syndrome Diseases 0.000 description 7
• 230000001939 inductive effect Effects 0.000 description 7
• 230000002757 inflammatory effect Effects 0.000 description 7
• 239000008101 lactose Substances 0.000 description 7
• 208000032839 leukemia Diseases 0.000 description 7
• 239000012528 membrane Substances 0.000 description 7
• 238000011321 prophylaxis Methods 0.000 description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 description 7
• 230000004936 stimulating effect Effects 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 238000000108 ultra-filtration Methods 0.000 description 7
• 206010001367 Adrenal insufficiency Diseases 0.000 description 6
• 206010070545 Bacterial translocation Diseases 0.000 description 6
• 102000011632 Caseins Human genes 0.000 description 6
• 108010076119 Caseins Proteins 0.000 description 6
• 206010067281 Portopulmonary hypertension Diseases 0.000 description 6
• 208000021068 Pulmonary arterial hypertension associated with portal hypertension Diseases 0.000 description 6
• 208000017515 adrenocortical insufficiency Diseases 0.000 description 6
• 239000000443 aerosol Substances 0.000 description 6
• 230000007375 bacterial translocation Effects 0.000 description 6
• 230000017531 blood circulation Effects 0.000 description 6
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
• 235000021240 caseins Nutrition 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 210000003494 hepatocyte Anatomy 0.000 description 6
• 201000004515 hepatopulmonary syndrome Diseases 0.000 description 6
• 230000036039 immunity Effects 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 206010022000 influenza Diseases 0.000 description 6
• 210000002540 macrophage Anatomy 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 210000004379 membrane Anatomy 0.000 description 6
• 206010034674 peritonitis Diseases 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 244000144977 poultry Species 0.000 description 6
• 210000000229 preadipocyte Anatomy 0.000 description 6
• 201000009104 prediabetes syndrome Diseases 0.000 description 6
• 230000003248 secreting effect Effects 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 230000000638 stimulation Effects 0.000 description 6
• 210000002784 stomach Anatomy 0.000 description 6
• 235000000346 sugar Nutrition 0.000 description 6
• 230000001629 suppression Effects 0.000 description 6
• 206010001854 Altered state of consciousness Diseases 0.000 description 5
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 5
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 5
• 241000271566 Aves Species 0.000 description 5
• 208000031229 Cardiomyopathies Diseases 0.000 description 5
• 102000019034 Chemokines Human genes 0.000 description 5
• 108010012236 Chemokines Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
• 108090000284 Pepsin A Proteins 0.000 description 5
• 102000057297 Pepsin A Human genes 0.000 description 5
• 101150016222 SNAT1 gene Proteins 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000005018 casein Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 239000012530 fluid Substances 0.000 description 5
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 238000007918 intramuscular administration Methods 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 229940111202 pepsin Drugs 0.000 description 5
• 210000002381 plasma Anatomy 0.000 description 5
• 229920000642 polymer Polymers 0.000 description 5
• 230000035935 pregnancy Effects 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000001225 therapeutic effect Effects 0.000 description 5
• 238000002255 vaccination Methods 0.000 description 5
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• 208000000044 Amnesia Diseases 0.000 description 4
• 206010008909 Chronic Hepatitis Diseases 0.000 description 4
• 208000007465 Giant cell arteritis Diseases 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• 244000068988 Glycine max Species 0.000 description 4
• 241000711549 Hepacivirus C Species 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 208000026139 Memory disease Diseases 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 230000029662 T-helper 1 type immune response Effects 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000005784 autoimmunity Effects 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 150000001720 carbohydrates Chemical class 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• -1 cell debris Substances 0.000 description 4
• 239000006285 cell suspension Substances 0.000 description 4
• 239000000470 constituent Substances 0.000 description 4
• UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000004069 differentiation Effects 0.000 description 4
• 235000013345 egg yolk Nutrition 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 239000002158 endotoxin Substances 0.000 description 4
• 230000002949 hemolytic effect Effects 0.000 description 4
• 238000010562 histological examination Methods 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 239000002955 immunomodulating agent Substances 0.000 description 4
• 230000001771 impaired effect Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 210000004347 intestinal mucosa Anatomy 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 201000003723 learning disability Diseases 0.000 description 4
• 229920006008 lipopolysaccharide Polymers 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000011777 magnesium Substances 0.000 description 4
• 230000006984 memory degeneration Effects 0.000 description 4
• 208000023060 memory loss Diseases 0.000 description 4
• 229960003151 mercaptamine Drugs 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 210000004400 mucous membrane Anatomy 0.000 description 4
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 208000005069 pulmonary fibrosis Diseases 0.000 description 4
• 239000012064 sodium phosphate buffer Substances 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 206010043207 temporal arteritis Diseases 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 230000029069 type 2 immune response Effects 0.000 description 4
• 210000003462 vein Anatomy 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 230000003313 weakening effect Effects 0.000 description 4
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
• 102100026891 Cystatin-B Human genes 0.000 description 3
• 102000000541 Defensins Human genes 0.000 description 3
• 108010002069 Defensins Proteins 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 208000016192 Demyelinating disease Diseases 0.000 description 3
• 206010012305 Demyelination Diseases 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 229930186217 Glycolipid Natural products 0.000 description 3
• 101000912191 Homo sapiens Cystatin-B Proteins 0.000 description 3
• 208000035150 Hypercholesterolemia Diseases 0.000 description 3
• 208000001953 Hypotension Diseases 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 101100310622 Mus musculus Soga1 gene Proteins 0.000 description 3
• 208000037581 Persistent Infection Diseases 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 206010067268 Post procedural infection Diseases 0.000 description 3
• 208000033255 Progressive myoclonic epilepsy type 1 Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 210000003486 adipose tissue brown Anatomy 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 210000001367 artery Anatomy 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 210000003719 b-lymphocyte Anatomy 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 239000004067 bulking agent Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000007812 deficiency Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 210000000969 egg white Anatomy 0.000 description 3
• 235000014103 egg white Nutrition 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 238000004108 freeze drying Methods 0.000 description 3
• 150000002339 glycosphingolipids Chemical class 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 230000036543 hypotension Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000006058 immune tolerance Effects 0.000 description 3
• 229940124622 immune-modulator drug Drugs 0.000 description 3
• 210000004153 islets of langerhan Anatomy 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 210000001865 kupffer cell Anatomy 0.000 description 3
• 210000000265 leukocyte Anatomy 0.000 description 3
• 201000007270 liver cancer Diseases 0.000 description 3
• 208000014018 liver neoplasm Diseases 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 239000012139 lysis buffer Substances 0.000 description 3
• 210000005075 mammary gland Anatomy 0.000 description 3
• 235000013372 meat Nutrition 0.000 description 3
• 201000001441 melanoma Diseases 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 230000001717 pathogenic effect Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 235000002020 sage Nutrition 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 230000003614 tolerogenic effect Effects 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 210000000636 white adipocyte Anatomy 0.000 description 3
• ZFGOPJASRDDARH-UHFFFAOYSA-N 3-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene Chemical compound C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C(C2)C1(C)CCC2OC1CC2=CCC3C4CCC(C(C)CCCC(C)C)C4(C)CCC3C2(C)CC1 ZFGOPJASRDDARH-UHFFFAOYSA-N 0.000 description 2
• LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 102000014777 Adipokines Human genes 0.000 description 2
• 108010078606 Adipokines Proteins 0.000 description 2
• 208000008190 Agammaglobulinemia Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 208000032467 Aplastic anaemia Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 108060000903 Beta-catenin Proteins 0.000 description 2
• 102000015735 Beta-catenin Human genes 0.000 description 2
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 2
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 2
• 208000032928 Dyslipidaemia Diseases 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
• 208000003807 Graves Disease Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 241000700721 Hepatitis B virus Species 0.000 description 2
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
• QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 2
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• 108010063045 Lactoferrin Proteins 0.000 description 2
• 102000010445 Lactoferrin Human genes 0.000 description 2
• 208000017170 Lipid metabolism disease Diseases 0.000 description 2
• 102000043129 MHC class I family Human genes 0.000 description 2
• 108091054437 MHC class I family Proteins 0.000 description 2
• 208000027530 Meniere disease Diseases 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 101710138657 Neurotoxin Proteins 0.000 description 2
• 241001631646 Papillomaviridae Species 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 241000286209 Phasianidae Species 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 206010036030 Polyarthritis Diseases 0.000 description 2
• 206010065159 Polychondritis Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 241000282849 Ruminantia Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• 206010052428 Wound Diseases 0.000 description 2
• 210000000683 abdominal cavity Anatomy 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 210000005006 adaptive immune system Anatomy 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 239000000478 adipokine Substances 0.000 description 2
• 210000000593 adipose tissue white Anatomy 0.000 description 2
• 208000002353 alcoholic hepatitis Diseases 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
• 235000011130 ammonium sulphate Nutrition 0.000 description 2
• 239000003674 animal food additive Substances 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 238000000149 argon plasma sintering Methods 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 244000052616 bacterial pathogen Species 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 208000000594 bullous pemphigoid Diseases 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 102000014509 cathelicidin Human genes 0.000 description 2
• 108060001132 cathelicidin Proteins 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 210000002421 cell wall Anatomy 0.000 description 2
• 230000007969 cellular immunity Effects 0.000 description 2
• 235000013351 cheese Nutrition 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 208000024207 chronic leukemia Diseases 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000004154 complement system Effects 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 230000000139 costimulatory effect Effects 0.000 description 2
• 201000003278 cryoglobulinemia Diseases 0.000 description 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000000688 enterotoxigenic effect Effects 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 230000020764 fibrinolysis Effects 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000035876 healing Effects 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 235000020256 human milk Nutrition 0.000 description 2
• 210000004251 human milk Anatomy 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• 208000006575 hypertriglyceridemia Diseases 0.000 description 2
• 230000003832 immune regulation Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 229940121354 immunomodulator Drugs 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
• 210000001596 intra-abdominal fat Anatomy 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 2
• 230000006651 lactation Effects 0.000 description 2
• 229940078795 lactoferrin Drugs 0.000 description 2
• 235000021242 lactoferrin Nutrition 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 201000011486 lichen planus Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 208000018191 liver inflammation Diseases 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 244000000010 microbial pathogen Species 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000001483 mobilizing effect Effects 0.000 description 2
• 210000004877 mucosa Anatomy 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000000581 natural killer T-cell Anatomy 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 239000002581 neurotoxin Substances 0.000 description 2
• 231100000618 neurotoxin Toxicity 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 230000007505 plaque formation Effects 0.000 description 2
• 208000030428 polyarticular arthritis Diseases 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• 208000007232 portal hypertension Diseases 0.000 description 2
• 230000008092 positive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 230000009711 regulatory function Effects 0.000 description 2
• 201000003068 rheumatic fever Diseases 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 239000013049 sediment Substances 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 229910001220 stainless steel Inorganic materials 0.000 description 2
• 239000010935 stainless steel Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 208000004611 Abdominal Obesity Diseases 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 102000011690 Adiponectin Human genes 0.000 description 1
• 108010076365 Adiponectin Proteins 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
• 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 241000272814 Anser sp. Species 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010071155 Autoimmune arthritis Diseases 0.000 description 1
• 206010069002 Autoimmune pancreatitis Diseases 0.000 description 1
• 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
• 108020000946 Bacterial DNA Proteins 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 238000009010 Bradford assay Methods 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
• 241001164374 Calyx Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 206010065941 Central obesity Diseases 0.000 description 1
• 108010004103 Chylomicrons Proteins 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
• 208000011038 Cold agglutinin disease Diseases 0.000 description 1
• 206010009868 Cold type haemolytic anaemia Diseases 0.000 description 1
• 208000002881 Colic Diseases 0.000 description 1
• 241000272201 Columbiformes Species 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 238000000018 DNA microarray Methods 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 241001643597 Evas Species 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 206010017711 Gangrene Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019837 Hepatocellular injury Diseases 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010021074 Hypoplastic anaemia Diseases 0.000 description 1
• 241000692870 Inachis io Species 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 206010023379 Ketoacidosis Diseases 0.000 description 1
• 208000007976 Ketosis Diseases 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• 101800001155 Latency-associated peptide Proteins 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 240000006240 Linum usitatissimum Species 0.000 description 1
• 235000004431 Linum usitatissimum Nutrition 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
• 208000024556 Mendelian disease Diseases 0.000 description 1
• 229920000881 Modified starch Chemical class 0.000 description 1
• 101100181592 Mus musculus Lep gene Proteins 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 241000272458 Numididae Species 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102000004264 Osteopontin Human genes 0.000 description 1
• 108010081689 Osteopontin Proteins 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 206010034133 Pathogen resistance Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 208000004880 Polyuria Diseases 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
• 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007156 Resistin Human genes 0.000 description 1
• 108010047909 Resistin Proteins 0.000 description 1
• 241000589970 Spirochaetales Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 241000272534 Struthio camelus Species 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 239000005862 Whey Substances 0.000 description 1
• 102000007544 Whey Proteins Human genes 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• NTOZOESJXIBDLD-UHFFFAOYSA-L [Ca+2].[O-]S(=O)S([O-])(=O)=O Chemical compound [Ca+2].[O-]S(=O)S([O-])(=O)=O NTOZOESJXIBDLD-UHFFFAOYSA-L 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000024340 acute graft versus host disease Diseases 0.000 description 1
• 231100000354 acute hepatitis Toxicity 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000008476 aike Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 229960002478 aldosterone Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 230000003113 alkalizing effect Effects 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 108010065183 antilipopolysaccharide antibodies Proteins 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000005775 apoptotic pathway Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 210000003567 ascitic fluid Anatomy 0.000 description 1
• 230000000923 atherogenic effect Effects 0.000 description 1
• 230000006470 autoimmune attack Effects 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 229910002056 binary alloy Inorganic materials 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229940088623 biologically active substance Drugs 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 210000001593 brown adipocyte Anatomy 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 229940078456 calcium stearate Drugs 0.000 description 1
• 235000011132 calcium sulphate Nutrition 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 229940021722 caseins Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 210000000991 chicken egg Anatomy 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 208000017760 chronic graft versus host disease Diseases 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 210000003040 circulating cell Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000005352 clarification Methods 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 108700021073 cold agglutinins Proteins 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010924 continuous production Methods 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000012149 elution buffer Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 231100000249 enterotoxic Toxicity 0.000 description 1
• 230000002242 enterotoxic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 210000002907 exocrine cell Anatomy 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 235000020243 first infant milk formula Nutrition 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 210000003736 gastrointestinal content Anatomy 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 229940049654 glyceryl behenate Drugs 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 235000003642 hunger Nutrition 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000002727 hyperosmolar Effects 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 230000001096 hypoplastic effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000037189 immune system physiology Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 229960003971 influenza vaccine Drugs 0.000 description 1
• 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000003914 insulin secretion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000005732 intercellular adhesion Effects 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 230000008944 intestinal immunity Effects 0.000 description 1
• 208000011140 intestinal infectious disease Diseases 0.000 description 1
• 230000002361 ketogenic effect Effects 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 230000008949 local secretion Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 210000003563 lymphoid tissue Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940057948 magnesium stearate Drugs 0.000 description 1
• 238000007898 magnetic cell sorting Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000009115 maintenance therapy Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 231100001016 megaloblastic anemia Toxicity 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229920000609 methyl cellulose Chemical class 0.000 description 1
• 239000001923 methylcellulose Chemical class 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 244000005706 microflora Species 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 235000021243 milk fat Nutrition 0.000 description 1
• 239000011707 mineral Chemical class 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000002715 modification method Methods 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 230000011234 negative regulation of signal transduction Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 208000015015 neurological dysfunction Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 239000002547 new drug Substances 0.000 description 1
• 230000000683 nonmetastatic effect Effects 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 231100000822 oral exposure Toxicity 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 201000002526 pancreas sarcoma Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• 230000007414 peripheral immune response Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 210000003800 pharynx Anatomy 0.000 description 1
• 230000037081 physical activity Effects 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 206010036067 polydipsia Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000007112 pro inflammatory response Effects 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000012121 regulation of immune response Effects 0.000 description 1
• 210000002707 regulatory b cell Anatomy 0.000 description 1
• 229940108461 rennet Drugs 0.000 description 1
• 108010058314 rennet Proteins 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 210000004767 rumen Anatomy 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000007974 sodium acetate buffer Substances 0.000 description 1
• PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
• 235000010378 sodium ascorbate Nutrition 0.000 description 1
• 229960005055 sodium ascorbate Drugs 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
• 238000000527 sonication Methods 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000037351 starvation Effects 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960004274 stearic acid Drugs 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 208000023516 stroke disease Diseases 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• HPINPCFOKNNWNW-UHFFFAOYSA-N thiete Chemical compound C1SC=C1 HPINPCFOKNNWNW-UHFFFAOYSA-N 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 239000000522 vaginal cream Substances 0.000 description 1
• 239000006216 vaginal suppository Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004393 visual impairment Effects 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 235000008939 whole milk Nutrition 0.000 description 1